drugset / Trial / NCT06545682
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.
Timeline
- Start
- 2024-10-15
- Primary completion
- 2027-08-03
- Completion
- 2029-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpelisib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |